Holen Sie sich die Stockscreener-App
1.38
8.66%
0.11
Handel nachbörslich:
1.39
0.01
+0.72%
Schlusskurs vom Vortag:
$1.27
Offen:
$1.31
24-Stunden-Volumen:
2.12M
Relative Volume:
2.35
Marktkapitalisierung:
$147.12M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-4.0588
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
-32.35%
1M Leistung:
-37.84%
6M Leistung:
-66.09%
1J Leistung:
-65.84%
1-Tages-Spanne:
$1.29
$1.4495
1-Wochen-Bereich:
$1.26
$1.74
52-Wochen-Spanne:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.38 | 140.72M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 4.14B | 577.90M | 6.96 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Should value investors consider MaxCyte Inc.Game-Changing Investment Alerts - thegnnews.com
MaxCyte Inc. Breaks Losing Streak — Is the Trend ReversingFree Premium Stock Market Reports - beatles.ru
Chartists Watching For Breakout in MaxCyte Inc.Weekly Return Pick Forecast Reports Show Trend - beatles.ru
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement - TipRanks
BTIG Downgrades MaxCyte to Neutral Citing Ongoing Challenges for Cell and Gene Therapy Customers - AInvest
MaxCyte Shares Plummet After Analyst Downgrades and Missed Earnings Estimates - AInvest
MaxCyte Shares Fall After BTIG Downgrade - MarketScreener
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
BTIG Downgrades MaxCyte to Neutral From Buy - MarketScreener
MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns - Investing.com
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
MaxCyte signs platform license agreement with Adicet Bio - MSN
MaxCyte Inc Q2 2025 Earnings: Revenue Falls Short at $8.5 Million, Net Loss Widens to $12.4 Million - AInvest
MaxCyte, Inc. (NASDAQ:MXCT) Q2 2025 Earnings Call Transcript - Insider Monkey
Maxcyte, Inc. shares rise 1.40% after-hours despite William Blair downgrading to Market Perform. - AInvest
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates - MSN
MaxCyte revises 2025 core revenue guidance to $29.5M-$32.5M amid customer program consolidation - MSN
Maxcyte's 31% Intraday Plunge: Earnings Woes and Sector Turbulence Spark Investor Panic - AInvest
MaxCyte Disappoints With Lower Revenue And Guidance For 2025 - Finimize
William Blair Downgrades MaxCyte to Market Perform From Outperform - MarketScreener
MaxCyte downgraded to Market Perform from Outperform at William Blair - TipRanks
Maxcyte, Inc. shares fall 11.76% premarket after Q2 revenue misses analyst estimates. - AInvest
MaxCyte stock downgraded by William Blair to Market Perform on weak guidance - Investing.com Australia
MaxCyte's Q2 2025 Earnings Call: Unpacking Key Contradictions in Growth and Manufacturing Strategy - AInvest
MaxCyte Updates 2025 Revenue Guidance to $29.5M-$32.5M Amid Customer Program Consolidation - AInvest
Earnings call transcript: MaxCyte misses Q2 revenue forecast amidst stock dip - Investing.com
MaxCyte (MXCT) Q2 Revenue Drops 18% - AOL.com
Maxcyte 2025 Q2 Earnings Worse Performance as Net Loss Widens 31.8% - AInvest
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges - Investing.com Nigeria
MaxCyte Q3 2025 presentation slides: SPL portfolio expands despite market challenges By Investing.com - Investing.com South Africa
Cell-engineering firm MaxCyte Q2 revenue misses analyst estimates - MarketScreener
MaxCyte Reports Q2 2025 Financial Results - TipRanks
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance - Morningstar
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation - Stock Titan
Heatmap Data Shows High Activity in MaxCyte Inc. SectorInvestment Strategy Designed for Capital Protection - beatles.ru
What are analysts’ price targets for MaxCyte Inc. in the next 12 monthsBreakout profit opportunities - Jammu Links News
How does MaxCyte Inc. generate profit in a changing economyLightning-fast growth - Jammu Links News
What are the latest earnings results for MaxCyte Inc.Achieve breakthrough financial results - Jammu Links News
What institutional investors are buying MaxCyte Inc. stockFind the best stocks for sustainable growth - Jammu Links News
What analysts say about MaxCyte Inc. stockInvest confidently with professional market insights - Jammu Links News
What is MaxCyte Inc. company’s growth strategyBuild a strong portfolio for long-term success - Jammu Links News
What are the technical indicators suggesting about MaxCyte Inc.Build wealth steadily with smart stock selection - Jammu Links News
Should I hold or sell MaxCyte Inc. stock in 2025Maximize gains with data-driven trading alerts - Jammu Links News
Exit strategy if you’re trapped in MaxCyte Inc.Chart Risk Profile for Capital Preservation - Newser
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Soleymannezhad Ali | Chief Commercial Officer |
Mar 18 '25 |
Sale |
3.18 |
1,211 |
3,850 |
59,439 |
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):